National Cancer Institute

Because bacteria naturally grab the attention of immune cells, they can help trigger an immune response against cancer.

The new study’s results support a shift in radiation therapy for prostate cancer that has been underway in the United States.

Black people make up about 14% of the U.S. population but only 5% to 7% of clinical trial participants.

Nivolumab (Opdivo) is already used as a stand-alone treatment for advanced Hodgkin lymphoma that has returned after first-line treatment.

In a study, extended lymph node surgery did not reduce the risk of the disease recurring or death, compared with the standard surgery.

Palliative care can be given to people at any stage of their disease to help manage their physical symptoms and emotional issues.

As more people with cancer use medical marijuana, oncologists face a deficit of data and feel ill-equipped to properly answer.

Hospitals big and small face multiple barriers in establishing and maintaining programs for adolescents and young adults with cancer.

No drugs are approved in the United States or Europe to treat wasting syndrome, so the results with ponsegromab are promising.

Leiomyosarcoma is a malignant tumor of smooth muscle cells; it’s most common in the uterus, abdomen or pelvis.

Osteonecrosis of the jaw linked to bone-modifying drugs is not as rare as once thought; meds are used if cancer spreads to the bone.

False positives on a mammogram are apparent abnormalities that, after further evaluation, are found not to be cancer.

This discovery provides an opportunity for developing treatments that may potentially prevent breast cancer from spreading.

Analysis of proteogenomic data opens up entirely new avenues for attacking cancer.

People taking Gleevec (imatinib) to treat certain gastrointestinal stromal tumors (GISTs) should continue until the disease gets worse.

An ancient virus-derived DNA fragment known as LTR10 can act as an “on switch” for a wide variety of cancers.

The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.